CRMI China Regenerative Medicine International L : BLB International Company Limited at a total consideration of HK$36 million Acquire Shares of CRMI

[Press Release]

China Regenerative Medicine International Limited

(Stock Code: 8158.HK)

BLB International Company Limited at a total consideration of

HK$36 million Acquire Shares of CRMI

(25 January, 2018 - Hong Kong) - China Regenerative Medicine International Limited ("CRMI" or the "Company," stock code: 8158.HK, collectively the "Group") is pleased to announce that CRMI introduces BLB International Company Limited, ("BLB", Stock code: SHE: 002286) as a substantial shareholder, at a total consideration of HK$36 million, indicating that the Company is pushing forward the "Big Health" industry with capital-based strategy.

Regarding the acquisition, All Favour Holdings Limited, a substantial shareholder of the Company intended to dispose of 2 billion shares of the Company (representing 11.37% of the issued share capital of the Company) to BLB. CRMI combines national strategy to upgrade the industrial development, expand from regenerative medical area to the Big Health industry, including precision medical treatment, combination of medical care and pension, food supplements, health care management and anti-aging industries. The Group looks forward to the synergistic effect with BLB and create more win-win situation.

As the leading functional-sugar enterprise in the PRC, BLB provides high-end products and value-added services to high-end customers, its products are exported to more than fifty countries and regions including United States, Japan, Belgium, France, Korea, Singapore and Australia, etc., It forms strategic cooperation partnership with the world's well-known brands such as Coca-Cola, Pepsi, Erie and Mengniu, etc., starting the BLB's new era of 'functional sugar across the globe, BLB shines in five continents" . Meanwhile, the Company has gradually established effective sales distribution channels and service networks, the sales performance of different product lines has achieved significant growth. In addition, it implements product upgrade strategy, to realize effective links betweenproduct-market, product-service, product-brand, single product-whole industrial chain through different means including product innovation, technology innovation and management innovation.

"13th Five-Year Plan" proposed to officially upgrade the healthy China to "national strategy", suggesting the goal of building a prosperous society, related to optimize national health policy by adhering to the principles of public health and illness prevention. According to marketing analysis, in the past three to five years, China's big health industry accounted for less than 2% of the global market with a big room for development. It is predicted China will continue to grow at a high speed in the coming years which will increase the corresponding business opportunities.

- END -

About BLB International Company Limited

BLB International Company Limited, a wholly-owned subsidiary of Baolingbao Biology Company limited. BLB International Company Limited was founded in 1997, the national key high-tech enterprise and the national key agricultural industrialization leading enterprise specialized in biological functional sugar. It is the first domestic enterprise which is engaged in industrial production of oligosaccharides, and the first A-share listed company to pass the US FDA site audit. There are scientific research institutes such as State-owned Enterprise Technology Center, National Sugar Engineering Research Center and National Regional Joint Engineering Laboratory, etc. There are academician workstations, postdoctoral workstations and positions of "Mount Tai scholars", and a "creative, innovative, creative and creative, A passenger "five-in-one innovation system.

Three kinds of products such as oligosaccharide maltose, high purity sialyloligosaccharide and fermentation glutamine have filled the gap in our country. More than 40 invention patents have been authorized by the state and presided over or participated in the formulation of more than 20 international and national standards. Well-deserved founder and leader of the sugar industry.

About China Regenerative Medicine International Limited

China Regenerative Medicine International Limited, listed on the GEM Board of The Stock Exchange (stock code: 8158) since 2001, is China's first high-end new- technology enterprise principally engaged in research and development,production and sales of tissue engineering and regenerative medicine products.

The Group has built up four major business segments, namely tissue engineering, cell therapy, cosmetics and hospital management. It has launched several iconic products including 'ActivSkin', the only tissue-engineered skin developed in China and 'Acornea', the world's first bio-engineered cornea which completed its clinical trials. The Company has applied for more than 140 domestic and overseas patents. Leveraging on its "CRMI Technology Centre at the University of Oxford", the

Company is now engaged in construction of a whole industry chain of cell therapy.

For more details, please visitwww.crmi.hk